Navidea: The Future Of The Company Will Be Borne On The Back Of Lymphoseek
The offering thru Crede CG in Sep 2013 has sparked theories about why the company cannot sustain a $2 price.
Trending on the Topix Network
Mon Mar 10, 2014
Navidea Biopharmaceuticals: 4 Reasons To Buy This $2 Lottery Ticket
Practicing 'Shotgun Investing' or taking much smaller positions in a greater variety of stocks evens out the volatility in the sector.
Fri Mar 07, 2014
Navidea Biopharmaceuticals, Inc. Files (8-K) Disclosing Entry into a...
NAVIDEA BIOPHARMACEUTICALS, INC. FILES Disclosing Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Triggering Events That Accelerate or Increase ... (more)
Thu Mar 06, 2014
Navidea Biopharmaceuticals (NAVB) Releases Quarterly Earnings...
Navidea Biopharmaceuticals issued its quarterly earnings data on Thursday. The company reported earnings per share for the quarter, missing the analysts' consensus estimate of by $0.02, AnalystRatings.Net reports.
Navidea Biopharmaceuticals Closes $30 Million Loan with Oxford Finance, LLC
Navidea believes the Oxford loan provides enhanced working capital with no balance sheet restrictions or covenants, lowers the interest rate and lengthens the interest-only period on the Company's debt, and augments the Company's financial flexibility at a critical time in its growth.
Wed Mar 05, 2014
Navidea Announces Acceptance for Review of an Additional sNDA to Further Expand LymphoseekA Labeling
Navidea Biopharmaceuticals, Inc. , a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the U.S. Food and Drug Administration has accepted for review an additional Supplemental New Drug Application for the proposed expanded label for Lymphoseek Injection to support broader and more flexible use in ... (more)
Mon Mar 03, 2014
Press release distribution, EDGAR filing, XBRL, regulatory filings
BYD Company Ltd placed 5th in the China National rankin... Point B Honored For a Decade of Employer Excellence: Named One of the Top Two Medium-Sized Companies to Work For in Oregon )--Point B Inc., a management consulting and venture investment firm, has been recognized as one of the top two best medium-sized companies to work for in Oregon ... (more)
Customer Interaction Solutions
Navidea Biopharmaceuticals to Announce Fourth Quarter and Full-Year...
Navidea Biopharmaceuticals, Inc. , a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Company will report its financial results for the fourth quarter and full-year 2013, on Thursday, March 6, 2014 before the market opens.
Fri Feb 28, 2014
Globe and Mail
Investor takes his cue from insider-trading signals
Half in basic materials stocks , the other half in stocks with significant insider trading .
Wed Feb 19, 2014
Navidea Biopharmaceuticals Adds New Member To Board Of Directors
Navidea Biopharmaceuticals, Inc. , a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Perry A. Karsen has been appointed to the Navidea Board of Directors.
Five Star Equities Issues New Research Reports on BRCD, NAVB, PRAN...
Brocade Communications Systems, Inc. shares declined 0.21 percent to close at $9.60 a share Tuesday.
Tue Feb 18, 2014
Customer Interaction Solutions
Navidea Announces Priority Review for the sNDA to Expand Lymphoseek...
Navidea Biopharmaceuticals, Inc. , a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the U.S. Food and Drug Administration has accepted the Supplemental New Drug Application and granted a Priority Review for the expanded use of Lymphoseek Injection indicated for sentinel lymph node detection in ... (more)
Thu Feb 13, 2014
Navidea Biopharmaceuticals Announces the Presentation of Manocepta ...
Navidea Biopharmaceuticals, Inc. , a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced data utilizing compounds from the Company's Manocept platform in models of rheumatoid arthritis are being presented by Thomas Rosol, DVM, PhD, DACVP from The Ohio State University at a Keystone Symposia on Molecular ... (more)